A new series of pyrazole, pyrimidine, pyrazolo[1,5-a]pyrimidine, imidazo[1,2-b]pyrazole and pyrazolo[5,1-b]quinazoline derivatives containing indane moiety are prepared by using N-(2,3-dihydro-1H-inden-5-yl)carbonohydrazonoyl dicyanide (2) as starting material to synthetic different heterocyclic compounds (3–11) by the reaction with different bifuncation reagents. Moreover, 4-((2,3-dihydro-1H-inden-5-yl)diazenyl)-1H-pyrazole-3,5-diamine (3) was taken as a precursor to prepare different pyrazolo[1,5-a]pyrimidine derivatives (12–20). The structures of newly synthesized compounds were confirmed on the basis of their IR, 1H NMR, 13C NMR, and mass spectral data. All compounds were evaluated as anti-inflammatory activity by using carrageenan-induced rat paw edema test. In comparison to the standard drug diclofenac sodium, compounds 3, 7, 9, and 11 exhibited potent activity than standard drug. The compounds 2 and 8 showed the most significant anti- anti-inflammatory with 64.83 and 63.95% inhibition of edema.

A novel series of N-1 arylidene amino imidazole-2-thiones were synthesized, identified using IR, ¹H-NMR, and ¹³C-NMR spectral data. Cytotoxic effect of the prepared compounds was carried out utilizing three cancer cell lines; MCF-7 breast cancer, HepG2 liver cancer, and HCT-116 colon cancer cell lines. Imidazole derivative 5 was the most potent of all against three cell lines. DNA flow cytometric analysis showed that, imidazoles 4d and 5 exhibit pre-G1 apoptosis and cell cycle arrest at G2/M phase. The results of the VEGFR-2 and B-Raf kinase inhibition assay revealed that compounds 4d and 5 displayed good inhibitory activity compared with reference drug erlotinib.

Synthesis and Cytotoxic Activity of Some Novel Thieno[2,3-d:4,5-d']Dipyrimidine Derivatives